ZURICH, April 20 (Reuters) - A German scientist studying
rare blood clots linked to AstraZeneca's COVID-19
vaccine said on Tuesday that Johnson & Johnson had
agreed to collaborate with him on research into similar events
associated with its own COVID-19 shot.
"We agreed today with the company that we will work
together," Andreas Greinacher, a scientist at Greifswald
University, said during a press conference where he outlined his
work seeking to explain the causes of the very rare clots that
developed in people given AstraZeneca's shot.
Greinacher's comments came as J&J said it stood ready to
restart its COVID-19 vaccine in Europe, where the region's
medical regulator on Tuesday said the benefits of the shot
outweigh the risk of very rare, potentially lethal blood clots.
(Reporting by John Miller)
Astrazeneca (AZN)
